We are live on ! Find out more
LPCN icon

Lipocine
LPCN

44 hedge funds and large institutions have $102M invested in Lipocine in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

869% more capital invested

Capital invested by funds: $10.5M → $102M (+$91.4M)

809% more call options, than puts

Call options by funds: $1.77M | Put options by funds: $195K

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

13% more funds holding

Funds holding: 39 → 44 (+5)

0.09% more ownership

Funds ownership: 0.71% → 0.79% (+0.09%)

Holders
44
Holders Change
+5
Holders Change %
+12.82%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
13
Reduced
9
Closed
4
Calls
$1.77M
Puts
$195K
Net Calls
+$1.58M
Net Calls Change
+$611K

Top Buyers

1
EI
EAM Investors
California
+$810K
2
Marshall Wace
Marshall Wace
United Kingdom
+$693K
3
Two Sigma Investments
Two Sigma Investments
New York
+$317K
4
BCM
Bridgeway Capital Management
Texas
+$218K
5
AWA
Aaron Wealth Advisors
Illinois
+$145K

Top Sellers

1
GCP
GSA Capital Partners
United Kingdom
-$437K
2
Morgan Stanley
Morgan Stanley
New York
-$228K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$166K
4
BlackRock
BlackRock
New York
-$36.7K
5
HF
HRT Financial
New York
-$23K
Name Holding Trade Value Shares
Change 		Change in
Stake
AWA
1
Aaron Wealth Advisors
Illinois
$85.8M +$145K +6,915 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$5.2M -$15.6K -746 -0.3%
BlackRock
3
BlackRock
New York
$2.14M -$36.7K -1,756 -2%
WE
4
Wealth Effects
Massachusetts
$2.04M +$1.72K +82 +0.1%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.13M -$1.7K -81 -0.2%
EI
6
EAM Investors
California
$901K +$810K +38,694 New
Marshall Wace
7
Marshall Wace
United Kingdom
$771K +$693K +33,098 New
Two Sigma Investments
8
Two Sigma Investments
New York
$493K +$317K +15,146 +251%
State Street
9
State Street
Massachusetts
$449K +$28K +1,340 +7%
Mercer Global Advisors
10
Mercer Global Advisors
Colorado
$423K -$4.92K -235 -1%
KAS
11
Kestra Advisory Services
Texas
$421K +$82.5K +3,941 +28%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$253K – – –
BCM
13
Bridgeway Capital Management
Texas
$242K +$218K +10,404 New
Northern Trust
14
Northern Trust
Illinois
$230K – – –
Two Sigma Advisers
15
Two Sigma Advisers
New York
$195K +$110K +5,258 +169%
VF
16
Virtu Financial
New York
$171K +$8.68K +415 +6%
Goldman Sachs
17
Goldman Sachs
New York
$121K +$91.6K +4,378 +524%
MML Investors Services
18
MML Investors Services
Massachusetts
$105K – – –
LPL Financial
19
LPL Financial
California
$96K +$9.23K +441 +12%
Ameriprise
20
Ameriprise
Minnesota
$91K – – –
CL
21
Choreo LLC
Illinois
$89K – – –
Citadel Advisors
22
Citadel Advisors
Florida
$86K +$33.9K +1,620 +77%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$76K – – –
Charles Schwab
24
Charles Schwab
California
$69K – – –
Morgan Stanley
25
Morgan Stanley
New York
$55K -$228K -10,908 -82%
1
2

LPCN Hedge Fund Activity: Q1 2022 in Review

44 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2022, worth a combined $102M — up 869% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new LPCN positions and 4 closed out — a net gain of 5 holders — while 13 added to existing stakes and 9 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $810K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $437K sold.

  • 44 institutional investors held Lipocine (LPCN) as of Q1 2022, up from 39 in Q4 2021.
  • Funds reported $102M of Lipocine stock for Q1 2022, up 869% quarter-over-quarter.
  • 9 funds opened new Lipocine positions in Q1 2022 and 4 closed out, a net change of +5 holders.
  • The largest Lipocine buyer in Q1 2022 was EAM Investors, an estimated $810K added.
  • The largest Lipocine seller in Q1 2022 was GSA Capital Partners, an estimated $437K sold.

Based on aggregated 13F filings for Q1 2022.